US national health care spending slows, but still outpaces economic downturn

19 January 2009

Spending on health care in the USA grew 6.1% in 2007, to total $2,200.0 billion, or $7,421 per person. This was the slowest rate of growth since  1998 and 0.6 of a percentage point lower than the increase of 6.7% in  2006, according to a report by the Centers for Medicare & Medical  Services (CMS). However, such expenditure continues to outpace overall  US economic growth, which advanced 4.8% in 2007.

"This is another reminder that the cost of health care continues to be  a real and pressing concern facing the American public and the federal  government," said CMS Acting Administrator Kerry Weems, adding: "this  report - like the reports issued last year on the financial status of  Medicare and Medicaid - is a stark reminder that we must redouble our  ongoing efforts to reform the delivery of health care services in this  country to bring about the goal of affordable, high quality health for  all Americans."

The slower growth in 2007 was attributed mostly to a downturn in both  retail prescription drug spending and Medicare expenditures associated  with administering the scheme's benefits. Even as health care spending  growth slowed, the health spending share of the nation's Gross Domestic  Product continued to climb, reaching 16.2% in 2007, up by 0.2 percentage  point from 2006.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight